

1 Long term anti-SARS-CoV-2 antibody kinetics and correlate of 2 protection against Omicron BA.1/BA.2 infection

3

4 Javier Perez-Saez^{1,2,*}, María-Eugenia Zaballa¹, Julien Lamour¹, Sabine Yerly³, Richard
5 Dubos¹, Delphine Courvoisier⁴, Jennifer Villers¹, Jean-François Balavoine⁵, Didier Pittet^{5,6},
6 Omar Kherad^{5,7}, Nicolas Vuilleumier^{3,5}, Laurent Kaiser^{3,5,8,9}, Idris Guessous^{10,11#}, Silvia
7 Stringhini^{1,12#}, Andrew S. Azman^{1,2#} on behalf of the Specchio-COVID19 study group

8

9 1 Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals,
10 Geneva, Switzerland

11 2 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
12 United States

13 3 Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva,
14 Switzerland

15 4 General Directorate of Health, Geneva, Switzerland

16 5 Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland

17 6 Infection Control Program and World Health Organization Collaborating Centre on Patient Safety,
18 Geneva University Hospitals, Geneva, Switzerland

19 7 Division of Internal Medicine, Hôpital de la Tour, Geneva, Switzerland

20 8 Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva,
21 Switzerland

22 9 Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland

23 10 Department of Health and Community Medicine, Faculty of Medicine, University of Geneva,
24 Geneva, Switzerland

25 11 Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva,
26 Switzerland

27 12 University Centre for General Medicine and Public Health, University of Lausanne, Lausanne,
28 Switzerland

29

30 # Equal contribution

31 * Corresponding author: javier.perez@hcuge.ch

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 **Abstract**

33 Binding antibody levels against SARS-CoV-2 have shown to be correlates of protection
34 against infection with pre-Omicron lineages. This has been challenged by the emergence of
35 immune-evasive variants, notably the Omicron sublineages, in an evolving immune
36 landscape with high levels of cumulative incidence and vaccination coverage. This in turn
37 limits the use of commercially available high-throughput methods to quantify binding
38 antibodies as a tool to monitor protection at the population-level. In this work, we leverage
39 repeated serological measurements between April 2020 and December 2021 on 1'083
40 participants of a population-based cohort in Geneva, Switzerland, to evaluate anti-Spike
41 RBD antibody levels as a correlate of protection against Omicron BA.1/BA.2 infections
42 during the December 2021-March 2022 epidemic wave. We do so by first modeling antibody
43 dynamics in time with kinetic models. We then use these models to predict antibody
44 trajectories into the time period where Omicron BA.1/BA.2 were the predominant circulating
45 sub-lineages and use survival analyses to compare the hazard of having a positive SARS-
46 CoV-2 test by antibody level, vaccination status and infection history. We find that antibody
47 kinetics in our sample are mainly determined by infection and vaccination history, and to a
48 lesser extent by demographics. After controlling for age and previous infections (based on
49 anti-nucleocapsid serology), survival analyses show reveal a significant reduction in the
50 hazard of having a documented positive SARS-CoV-2 infection during the Omicron
51 BA.1/BA.2 wave with increasing antibody levels, reaching up to a three-fold reduction for
52 anti-S antibody levels above 800 IU/mL (HR 0.30, 95% CI 0.22-0.41). However, we did not
53 detect a reduction in hazard among uninfected participants. Taken together these results
54 indicate that anti-Spike RBD antibody levels, as quantified by the immunoassay used in this
55 study, are an indirect correlate of protection against Omicron BA.1/BA.2 for individuals with a
56 history of previous SARS-CoV-2 infection. Despite the uncertainty in what SARS-COV-2
57 variant will come next, these results provide reassuring insights into the continued
58 interpretation of SARS-CoV-2 binding antibody measurements as an independent marker of
59 protection at both the individual and population levels.-

60 **Introduction**

61 While by mid-2022 a large fraction of the global population had developed anti-SARS-CoV-2
62 binding antibodies through infection and/or vaccination (Bergeri et al., 2022; Zaballa et al.,
63 2022), it remains unclear whether seroprevalence results translate into prevalence of
64 effective protection against infection (Theel et al., 2020). Neutralizing antibodies may provide

65 a reliable correlate of protection against both infection and severe disease (Earle et al.,
66 2021; Gilbert et al., 2022; Khoury et al., 2021; Krammer, 2021). Neutralization assays are,
67 however, labor-intensive and challenging to use at a large scale, despite advances in high-
68 throughput surrogate assays (Fenwick et al., 2021).

69

70 Binding antibody measurements have been found to correlate with neutralization capacity
71 against the ancestral SARS-CoV-2 strain at different degrees depending on time post
72 infection/vaccination, and on immuno-assay (Earle et al., 2021; Goldblatt et al., 2022;
73 L'Huillier et al., 2021). Evidence for their more general use as correlate of protection is
74 mounting both from population-level (Earle et al., 2021; Goldblatt et al., 2022), as well as
75 individual-level studies in the context of vaccine trials (Dimeglio et al., 2022b; Feng et al.,
76 2021; Gilbert et al., 2022; Wei et al., 2021). These studies suggest that higher antibody
77 measurements after infection and/or vaccination tend to reduce subsequent infection risk
78 (Osman et al., 2021). However, most of these studies focused on the ancestral SARS-CoV-2
79 strain and it is yet to be clarified whether these results robustly extend to the Omicron
80 subvariants (Hertz et al., 2022; Zar et al., 2022).

81

82 The evaluation of binding antibody levels as correlates of protection is challenged by the
83 constant evolution of the anti-SARS-CoV-2 immune landscape through vaccination and
84 successive epidemic waves driven by different virus variants. Longitudinal antibody studies
85 up to 14 months follow-up have shown that antibody levels change with time since infection
86 and/or vaccination across individuals, and depending on the immuno-assays used for
87 detection (Eyran et al., 2022; Gallais et al., 2021; Peluso et al., 2021; Perez-Saez et al.,
88 2021). Characterization of long-term antibody kinetics provides an opportunity for leveraging
89 serological cohort studies to complement vaccine trials in evaluating binding antibody levels
90 as correlate of protection against future infections. By relying on binding antibody
91 immunoassays that are simple, standardized and widely used worldwide, the results of these
92 studies have the potential to be generalized to other settings despite their functional
93 limitation. These cohort studies might therefore contribute by assessing the extension of
94 results to different commercially-available immunoassays and a wider range of
95 infection/vaccination histories, in particular to non-vaccinated individuals.

96

97 In this study, we aim to evaluate the use of a commercially available immunoassay as a
98 correlate of protection in the Omicron era. We do so by leveraging repeated serological
99 measurements and reported infections on a population-based longitudinal cohort followed for
100 up to 20 months in the state of Geneva, Switzerland. We first characterize antibody
101 dynamics during the longitudinal serology period (April 2020 to December 2021) using

102 kinetic models fit to observed antibody measurements. We then project each individual's
103 antibody trajectories into the Omicron exposure period (December 2021 to March 2022) to
104 explore the relationship between projected antibody levels and having a SARS-CoV-2
105 positive test.

106 **Materials and methods**


107 **Study design**

108 This study uses data from the population-based Specchio-COVID19 cohort, composed of
109 adult participants recruited through serological surveys (Baysson et al., 2022; Stringhini et
110 al., 2021a, 2021b, 2020). Following their baseline serology, participants in this cohort are
111 regularly invited to complete online questionnaires, where they report SARS-CoV-2 test
112 results, disease severity and vaccination status, and can be proposed one or several
113 serological tests during the follow-up. Each participant coming for a follow-up serology
114 provided a venous blood sample and filled in a short paper questionnaire on site to
115 update/complete their information on infection and vaccination statuses.

116

117 In this study, our main analysis consisted of two steps. Firstly, we analyzed antibody
118 trajectories during the longitudinal serology period, when serological testing follow-up was
119 conducted (April 6th 2020, to December 17th 2021). Secondly, we evaluated correlates of
120 protection against infection during the “exposure period”, using information on SARS-CoV-2
121 infections from the surge of the Omicron BA.1 subvariant in the state of Geneva until the end
122 of the study period (December 25th 2021 to March 20th 2022) (Figure 1). In this period there
123 were no specific quarantine and isolation measures following SARS-CoV-2 infection nor
124 other specific recommendations in Geneva, which may have contributed to low virological
125 testing rates. During the exposure period Omicron BA.1 and BA.2 subvariants comprised
126 nearly all infections. From all participants of the Specchio-COVID19 cohort, in this analysis,
127 we only included those having at least two positive serologies and for whom we had
128 complete vaccination information by March 20th 2022 (Supplementary Material Figure S1).
129 During the study period, the only available COVID-19 vaccines in Switzerland were the
130 mRNA-BNT162b2/Comirnaty from Pfizer/BioNTech (since December 2020), mRNA-1273
131 from Moderna/US NIAID (since January 2021), and the Janssen Ad26.COVS.S COVID-19
132 vaccine (since October 2021).

133 This study was approved by the Geneva Cantonal Commission for Research Ethics (CCER
134 project number 2020-00881) and written informed consent was obtained from all
135 participants.



136 Immunoassays

137 For this study, we used the quantitative Elecsys anti-SARS-CoV-2 RBD immunoassay,
 138 which measures total antibodies (IgG/A/M) against the receptor binding domain of the virus
 139 spike (S) protein (#09 289 275 190, Roche-S, Roche Diagnostics, Rotkreuz, Switzerland).
 140 Seropositivity was defined using the cut-off provided by the manufacturer of ≥ 0.8 U/mL.
 141 Output test values were transformed to WHO international standard units by multiplying by a
 142 factor of 1.184. We calculated the intra-lot coefficient of variation (CV) for each batch of our
 143 internal positive control serum and the maximum CV (7.3%) was used to define uncertainty
 144 in serological measurements in the kinetic model described below (Supplementary Material
 145 Section S2). To identify past infections in vaccinated participants, we also measured total

146 levels of antibodies binding the nucleocapsid (N) protein using the semiquantitative Elecsys
147 anti-SARS-CoV-2 N immunoassay (#09 203 079 190, Roche-N). The three vaccines
148 available in Switzerland during the study period elicit a response exclusively to the Spike
149 protein of SARS-CoV-2, as opposed to infection, typically eliciting a response to both the N
150 and S virus proteins. Although not the focus of the main analysis, we also present anti-N
151 antibody trajectories in the Supplementary Material (Supplementary Material Section S3).

152 SARS-CoV-2 virological tests data

153 For the correlate of protection analysis, results of PCR and antigenic tests were extracted
154 from the ARGOS database up to March 20th 2022. The ARGOS database consists of a
155 general register of COVID-19 diagnostic tests performed in the state of Geneva since
156 February 2020 and is maintained by the state directorate for health (Genecand et al., 2021).
157 Data on test results from ARGOS were supplemented with additional information on COVID-
158 19 diagnostic tests (PCR or antigen-based rapid diagnostic tests [RDTs] including self-tests)
159 as self-reported by the participants through regular questionnaires.

160 Statistical analyses

161 **Antibody trajectories analysis.** In the first step of the analysis (“longitudinal serology”
162 period in Figure 1), we characterized antibody dynamics by fitting the observed antibody
163 trajectories to bi-phasic kinetic models (Pelleau et al., 2021). These models assume an initial
164 post-infection/vaccination antibody boost (increase in antibody levels at a given time post-
165 exposure) followed by initially fast then slower exponential decay. We here expanded these
166 models to account for multiple boosting events due to infection and/or vaccination. The size
167 of antibody boosts and decay in time are determined by age, sex and boosting history (the
168 sequence of infections and vaccine doses). We further accounted for observed individual-
169 level variability in anti-SARS-CoV-2 antibody kinetics. Inference was performed in a
170 Bayesian hierarchical framework incorporating uncertainty of the timing of infection events in
171 the absence of information on COVID-19 diagnostic tests. Model details are given in the
172 Supplementary Material (Section S4). Stan model code and minimal testing datasets are
173 available at https://github.com/UEP-HUG/serosuivi_2021_public.

174

175 **Survival analysis.** In the second step of the analysis, we evaluated binding antibody levels
176 as a correlate of protection against Omicron BA.1/BA.2 infections during the “exposure
177 period” (Figure 1) using survival analysis methods. The aim was to infer the effect of being
178 above different thresholds of binding antibody levels (as measured by the Roche-S
179 immunoassay) on the hazard of confirmed SARS-CoV-2 infection during the exposure

180 period. We focused on the exposure period from when Omicron BA.1 became dominant
181 (more than 80% of samples on Dec 25th 2021) up to the latest date for which we had access
182 to the state registry of SARS-CoV-2 test results (March 20th 2022). By this date Omicron
183 BA.2 had replaced Omicron BA.1 in Western Switzerland (90% vs. 10% of typed samples,
184 Figure 1). We excluded participants with either (a) no serology information after April 1st
185 2021, or (b) uncertain infection status during the Omicron exposure period due to missing
186 data (i.e. missing positive test result and missing self-reported absence of positive tests,
187 details in Supplementary Material Section S1). We used Cox proportional hazards model,
188 controlling for age and previous infection status based on our assumptions of the
189 relationship between variables (Supplementary Material Section S5). Given that we used
190 modeled antibody levels during the exposure period based on available serological prior
191 measurements, we excluded participants for whom a boosting event (infection and/or
192 vaccination) occurred between the last serological measurement and the start of the
193 exposure period if the modeled antibody level was below the threshold of interest
194 (Supplementary Material Section S1). Potential informative censoring due to vaccination
195 and/or infection during the Omicron exposure period was adjusted for through inverse
196 probability weighting as implemented in the ipw R package (Wal and Geskus, 2011).

197 **Results**

198 The cohort included in this study was composed of 1'083 adult participants, 55% of whom
199 were female and 91% were younger than 65 years (Table 1). Participants in the cohort had
200 few comorbidities and no immunosuppressive diseases in general. Among participants, 91%
201 had a history of SARS-CoV-2 infection (based on positive tests or anti-N serology as defined
202 in the Supplementary Material Section S1) and 58% were unvaccinated at the time of their
203 most recent serology (range of last serology dates November 16th 2020 – December 17th
204 2021, median June 21st 2021). Around half of participants with a history of infection based on
205 a positive anti-N serology did not have any diagnostic screening tests during the acute
206 phase of their infection (PCR or RDT) (58%). Most participants in the cohort had only two
207 positive serological tests (56%), and 10% had 4 or more seropositive samples. All event data
208 is presented in Supplementary Figure S2.

Table 1. Participant characteristics. Characteristics are given for the five encountered infection and vaccination history.

Characteristic	N = 1'083 ¹
Sex	
female	590 (55%)
male	493 (45%)
Age (years)	
18-64	988 (91%)
65+	95 (9%)
Infection/vaccination status at time of most recent serological test	
infected only	634 (58%)
vaccinated only	98 (9%)
infected prior to vaccination	310 (29%)
infected after vaccination	11 (1%)
infected prior to vaccination and re-infected after vaccination	30 (3%)
Virological confirmation among participants with history of infection (N=985)	
Virologically confirmed infection (self-reported or from ARGOS registry)	567 (58%)
No virological confirmation (anti-N positive serology)	418 (42%)
Vaccine type among vaccinated participants at time of last serological status (N=449)	
mRNA-1273 (Moderna/US NIAID)	247 (55%)
mRNA-BNT162b2/Comirnaty (Pfizer/BioNTech)	202 (45%)
# Positive Roche-S serological samples per participant within this study	
2	603 (55%)
3	374 (35%)
4	104 (10%)
5	1 (<0.1%)
¹ n (%)	

209

210

211 Antibody trajectories during the longitudinal serology period

212 Serological samples were collected from 1'083 participants between April 2020 and
213 December 2021, with follow-up times between first and last visits of up to 20 months
214 following infection and up to 8 months following vaccination (Figure 2a). Over this
215 longitudinal serology period, we did not observe anti-S-based seroreversion for any
216 participants (Figure 2b). Antibody levels following vaccination were distributed in the upper
217 range of the immunoassay's dynamic range (Figure 2b, Supplementary Figure S3), with
218 more than one in three samples collected at least 14 days after participant's latest vaccine
219 dose having values above the upper quantification limit of the test (33%, Figure 2d). Anti-N
220 antibody trajectories are shown in Supplementary Figure S4.
221





Figure 2. Anti-S binding antibodies level trajectories. a) Follow-up time distribution (time from participant's first to last serology) for samples collected prior ($n = 778$) and post ($n = 246$) vaccination when at least two positive samples were available. Note that participants may have multiple samples prior and post vaccination and may therefore appear in both categories. b) Trajectories for all participants ($n = 1'083$) by serological sampling date and according to vaccination status. c) Trajectories of pre-vaccination samples by time from virological confirmation when available ($n = 442$), along with violin plots of antibody levels in discrete arbitrary categories of time post confirmation (0-149, 150-249, 250-449, 450+ days). d) Trajectories post-vaccination by time from latest dose ($n = 246$). Dashed and dotted lines in panels b, c and d indicate upper quantification limit (2500 U/mL, equivalent to 2960 IU/mL) and threshold for positivity (0.8 U/mL, equivalent to 0.95 IU/mL) of the test, respectively.

222

223 To investigate how infection and vaccination history affects antibody levels, we fit kinetic
224 models to individual-level antibody trajectories. Mean antibody rises were similar among age
225 classes. Rises in anti-S binding antibody levels depended markedly on both infection and
226 vaccination history (Figure 3a, parameter estimates in Supplementary Table S2). The
227 weakest estimated anti-S boost were the ones following infection in unvaccinated
228 individuals, while the strongest boost was estimated following the first vaccine dose in
229 previously infected individuals. Among vaccinated and infected individuals the estimated
230 anti-S boost parameter decreased with the number of vaccine doses. Among uninfected
231 individuals the largest increase in anti-S levels occurred after the second vaccine dose, with
232 similar levels for the first and third doses. Mean antibody half-lives showed less variation
233 among boosting events, ranging from 50 days (95% CrI 30-100) following the second
234 vaccine dose in uninfected 18-64y individuals to 510 days (140-1360) in 65+ individuals with
235 two infections and one vaccine dose (Figure 3b). Estimated antibody half-lives were similar
236 across individuals both infected and vaccinated, regardless of the number of vaccine doses
237 received. In turn, antibodies decayed faster in uninfected individuals following the second
238 dose, as opposed to antibodies mounted with the first and third doses. Both boost level and
239 antibody decay rates had considerable although uncertain individual-level heterogeneity with
240 coefficients of variation of 5.1 (95% CrI 0.2-50.0) and 22.1 (0.3-65.5), respectively. These
241 kinetic parameter estimates along with inference on individual-level variability allowed us to
242 model antibody trajectories for each participant with strong agreement with available
243 serological measurements (Figure 3c, Supplementary Figure S5).

244



245

246 Survival analysis during the Omicron exposure period

247 In this second part of the analysis, we used survival analysis to evaluate the relationship
 248 between the projected anti-S binding antibody levels, as described above, and the hazard of
 249 infection during the Omicron exposure period (Figure 1). Data on virologically-confirmed
 250 infections during the exposure period (positive test or self-reported negative tests only, see
 251 Methods) were available for 967 out of the 1'083 participants, of whom we retained 900 with
 252 latest serology after April 1st 2021 (Supplementary Figure S1). The subsample included in
 253 this survival analysis was composed of 55% of female participants; 92% were younger than
 254 65 years; 80% had received at least one vaccine dose prior to the start of the Omicron
 255 exposure period (December 25th 2021); and 90% had at least one SARS-CoV-2 infection
 256 prior to the start of the exposure period (Supplementary Table S3). Out of these 900
 257 participants, 227 had a virologically-confirmed infection during the Omicron exposure period.
 258

259 We found that the hazard of having an Omicron BA.1/BA.2 infection for individuals with anti-
260 S binding antibody levels higher than a given arbitrary threshold, compared to those with
261 levels below that threshold, decreased down to a three-fold reduction in hazard at a
262 threshold of 800 IU/mL (hazard ratio, HR 0.30, 95% CI 0.22-0.41), and then plateaued for
263 higher antibody level thresholds (Figure 4a). In sensitivity analyses we found consistent
264 effect sizes across antibody thresholds using logistic regression, as well as using different
265 quantiles of the predicted antibody trajectories (Supplementary Material Section S6).

266

267 We however found that measured antibody-levels do not have the same meaning in terms of
268 correlate of protection whether a participant had a history of infection or not, independently
269 of antibody level (Figure 4b). Similar proportions of Omicron infections were observed
270 among vaccinated participants with no history of infection (and anti-N negative serology)
271 irrespective of their anti-S antibody levels being below or above the 800 IU/mL threshold.
272 Conversely, participants with a history of infection had lower hazard of infection when having
273 antibody levels above the 800 IU/mL threshold, regardless of their vaccination status (Figure
274 4b, bottom row). Thus, for this anti-S antibody levels threshold, effect estimates stratified by
275 infection and vaccination history showed no significant difference in hazard for uninfected
276 (vaccinated) participants (HR 1.05, 0.36-3.05), and a consistent hazard reduction for
277 participants with a history of infection whether they were vaccinated (HR 0.30, 0.07-1.21) or
278 not (HR 0.45, 0.19-1.06), although small sample sizes in some of these categories yielded
279 wide confidence intervals.

280




Figure 4. Omicron BA.1/BA.2 infection survival analysis. a) Cox hazard ratio estimates (dots, error bars give the 95% CI) based on proportional hazard models accounting for age and prior infection status across antibody level thresholds. b) Kaplan-Meier curves of the probability of non-infection by SARS-CoV-2 Omicron BA.1/BA.2 stratified by whether predicted antibody levels during the exposure period were above or below 800 IU/mL, shown for the overall analysis dataset, and stratified by infection and vaccination history. Day 0 corresponds to December 25th 2021, when Omicron BA.1 accounted for more than 80% of infections in the state of Geneva (Figure 1c). For this 800 IU/mL threshold, the overall sample size was of N=562 (flowchart in Supplementary Figure S1), subdivided into N=78 for “No prior infection and vaccinated”, N=155 for “Prior infected and non-vaccinated”, and N=329 for “Prior infection and vaccinated”.

281 Discussion

282 This longitudinal antibody study with follow-up times up to 20 months provided the
283 opportunity to understand long-term anti-SARS-CoV-2 antibody dynamics and to evaluate
284 binding antibody levels from a commercial widely available immunoassay as a correlate of
285 protection against infections during the Omicron BA.1/BA.2 era. Anti-S antibodies persisted
286 up to 20 months after the probable date of infection, with decay dynamics determined by
287 infection and vaccination history. Strongest and longest-lasting antibody boosts occurred
288 with vaccine doses following prior infection. Modelled antibody trajectories enabled the
289 evaluation of binding antibody levels as a correlate of protection against Omicron BA.1/BA.2
290 infections, for which we found an overall three-fold reduction in the hazard of reporting a
291 positive test for antibody levels above 800 IU/mL. Hazard reduction was however not
292 observed for non-infected participants, indicating that the validity of anti-S binding antibody
293 levels as correlates of protection for Omicron BA.1/BA.2 depends on infection history.

294
295 This study extends our previous work showing that anti-SARS-CoV-2 spike antibodies
296 remain detectable after 22 months past probable infection as measured with the Roche anti-
297 S immunoassay (Perez-Saez et al., 2021). Our kinetic modeling results support previous
298 findings indicating that antibody boost is strongest and longest lasting in vaccinees with a
299 history of infection (Dimeglio et al., 2022a; Eyran et al., 2022; Luo et al., 2021). In contrast
300 with previous findings, we found no significant difference in antibody boosting between age
301 groups and slower decay rates in adults 65 years and older (Gallais et al., 2021; Vanshylla
302 et al., 2021). The slower decay rates may be due to age-specific differences in disease
303 severity that we did not account for in these models, thus limiting the comparability of these
304 findings with previous studies due to differences in disease severity profiles. Furthermore,
305 we had a small number of participants over 65 years of age in our study and these age-
306 stratified results should be interpreted with caution. Finally, our results highlight the strong
307 individual-level variability in antibody dynamics, which has been shown in previous antibody
308 kinetic studies (Pelleau et al., 2021; Vanshylla et al., 2021).

309

310 Survival analysis results on Omicron BA.1/BA.2 infections are in line with previous findings
311 from vaccine trials targeting the ancestral strain and the Alpha variant, showing that binding
312 antibody levels are an informative correlate of protection against SARS-CoV-2 infection
313 (Feng et al., 2021; Gilbert et al., 2022). These trials had found similar effect sizes of around
314 five-fold reduction in risk of Alpha infections at anti-S antibody levels of 600 IU/mL (Feng et
315 al., 2021), and a halving of hazard by 10-fold increase in anti-S titers for ancestral strain
316 infections (Gilbert et al., 2022). Moreover our results are in line with available studies on
317 Omicron BA.1/BA.2 subvariants which have also found binding antibody levels to be
318 correlates of protection against infection using in-house immunoassays (Hertz et al., 2022;
319 Zar et al., 2022). On the other hand, we did not find differences in the hazard of having an
320 Omicron BA.1/BA.2 infection with anti-S antibody levels below or above a certain threshold
321 in the non-infected vaccinated group, as opposed to results reported for Delta infections
322 (Wei et al., 2021). Notably, this finding is supported by our recent work on neutralization
323 capacity in the Geneva population (Zaballa et al., 2022). Using the same immunoassay as in
324 this study and a cell-free Spike trimer-ACE2 binding-based surrogate neutralization assay
325 (Fenwick et al., 2021), we did not observe any significant correlation between anti-S binding
326 and neutralizing antibody levels against Omicron subvariants in uninfected participants, as
327 opposed to previously infected participants (Zaballa et al., 2022). These results can be
328 linked to growing evidence that hybrid immunity (infection plus vaccination) provides the
329 strongest protection against Omicron subvariant infections (Altarawneh et al. 2022, Zar et al.
330 2022, Goldblatt 2022). This infection history-specificity thus warrants care in the
331 interpretation of binding antibodies as correlates of protection against Omicron sub-lineages,
332 and could be immunoassay-dependent.

333

334 We note that it remains unclear whether these correlate of protection results extend to
335 subsequent Omicron subvariants (BA.4, BA.5, BA.2.75, BQ.1 and others), which have been
336 found, thanks to specific mutations, to have stronger immune-evasion capacity than the
337 parent BA.1 strain (Cao et al., 2022; Tan et al., 2022). Changes in immune evasion capacity
338 may theoretically, if multiple mutations accumulate on the spike protein, impact the level of
339 binding antibodies at which hazard reduction occurs as well as its effect size. Moreover, our
340 longitudinal serology follow-up was conducted before the circulation of the Omicron lineage
341 in Geneva. The interpretation of anti-S antibody levels measured with this immunoassay
342 following Omicron infections might need to be revisited in the light of evidence of reduced
343 test sensitivity towards antibodies targeting the Omicron Spike protein (Springer et al.,
344 2022).

345

346 This study has several limitations. Firstly, we only used the Roche Elecsys assay, which
347 measures total anti-S antibodies (IgA/M/G), whose levels may correlate differently with
348 overall immune function following infection or vaccination; other immunoassays may have
349 different antibody binding characteristics. Secondly, analyses in the 65+ subgroup are
350 limited by the small number of participants. Thirdly, our survival analysis to assess correlates
351 of protection was based on modeled antibody trajectories, and not on measurements at
352 defined time points as done in studies available from vaccine trials (Gilbert et al., 2022).
353 Although modeled trajectories matched well antibody participant-level measurements, the
354 survival analysis results are subject to modeling uncertainty. While sensitivity analysis using
355 the 2.5% and 97.5% prediction quantiles yielded qualitatively similar correlates of protection
356 results, other sources of modeling uncertainty cannot be excluded. Fourthly, a large
357 proportion of virologically-confirmed infections (44%, 101/227) were self-reported as
358 opposed to the other 56%, which were directly extracted from the state COVID-19 test
359 registry (ARGOS). Reassuringly, of the 1'083 participants in our longitudinal sample for
360 whom tests in the registry were available, self-reported positive tests with matching dates
361 were reported in 82% (491/599) of cases, thus suggesting a reasonable sensitivity of self-
362 reporting. Finally, both Omicron BA.1 and BA.2 subvariants circulated in the canton of
363 Geneva during the study exposure period and sequencing information on infection was not
364 available, thus precluding a differential correlate of protection analysis for both subvariants.

365

366 Overall, this study extends findings against previous SARS-CoV-2 variants showing that
367 anti-S binding antibody levels are a valid correlate of protection against Omicron BA.1/BA.2
368 infections. Importantly, we found that the validity of antibody levels as correlates of protection
369 depends on infection history as quantified with the immunoassay used in this study. Our
370 results highlight the imperfect nature of protection after vaccination and/or infection. Even
371 with perfect knowledge of infection and vaccination histories, inference about population-
372 level immunity continues to pose challenges. Future studies may benefit from the modeling
373 framework developed in this study to leverage longitudinal measurements to epidemiological
374 outcomes. Taken together, these conclusions motivate further investigation of how immune
375 landscape and immunoassay characteristics determine the interpretation of serological
376 surveys into population-levels of protection to inform public health decisions.

377 **Acknowledgements**

378 We thank Aglaé Tardin and the team of General Directorate of Health of Geneva for giving
379 us access to the ARGOS state registry, and the Hôpital de La Tour and the Clinique de

380 Carouge for allowing us to use their premises for the recruitment of participants. We are
381 deeply grateful to all the participants, without whom this study would not have been possible.

382 **Funding**

383 This study was funded by the Private Foundation of the Geneva University Hospitals and the
384 General Directorate of Health of the canton of Geneva. The funders had no role in study
385 design, data collection and analysis, decision to publish, or preparation of the manuscript.

386 References

- 387 Altarawneh, H.N., Chemaitelly, H., Ayoub, H.H., Tang, P., Hasan, M.R., Yassine, H.M., Al-Khatib,
388 H.A., Smatti, M.K., Coyle, P., Al-Kanaani, Z. and Al-Kuwari, E., 2022. Effects of previous
389 infection and vaccination on symptomatic omicron infections. *New England Journal of*
390 *Medicine*, 387(1), pp.21-34.
- 391 Baysson, H., Pennacchio, F., Wisniak, A., Zaballa, M.E., Pullen, N., Collombet, P., Lorthé, E., Joost,
392 S., Balavoine, J.-F., Bachmann, D., Azman, A., Pittet, D., Chappuis, F., Kherad, O., Kaiser,
393 L., Guessous, I., Stringhini, S., 2022. Specchio-COVID19 cohort study: a longitudinal follow-
394 up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland. *BMJ Open*
395 12, e055515. <https://doi.org/10.1136/bmjopen-2021-055515>
- 396 Bergeri, I., Whelan, M., Ware, H., Subissi, L., Nardone, A., Lewis, H.C., Li, Z., Ma, X., Valenciano, M.,
397 Cheng, B., Ariqi, L.A., Rashidian, A., Okeibunor, J., Azim, T., Wijesinghe, P., Le, L.-V.,
398 Vaughan, A., Pebody, R., Vicari, A., Yan, T., Yanes-Lane, M., Cao, C., Clifton, D.A., Cheng,
399 M.P., Papenburg, J., Buckeridge, D., Bobrovitz, N., Arora, R.K., Kerkhove, M.D.V., Group,
400 the U.S.C., 2022. Global SARS-CoV-2 seroprevalence: a systematic review and meta-
401 analysis of standardized population-based studies from Jan 2020-May 2022.
402 <https://doi.org/10.1101/2021.12.14.21267791>
- 403 Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., Yu, Y.,
404 Wang, P., Zhang, Z., Liu, P., An, R., Hao, X., Wang, Yao, Wang, J., Feng, R., Sun, H., Zhao,
405 L., Zhang, W., Zhao, D., Zheng, J., Yu, L., Li, C., Zhang, N., Wang, R., Niu, X., Yang, S.,
406 Song, X., Chai, Y., Hu, Y., Shi, Y., Zheng, L., Li, Z., Gu, Q., Shao, F., Huang, W., Jin, R.,
407 Shen, Z., Wang, Youchun, Wang, X., Xiao, J., Xie, X.S., 2022. BA.2.12.1, BA.4 and BA.5
408 escape antibodies elicited by Omicron infection. *Nature* 608, 593–602.
409 <https://doi.org/10.1038/s41586-022-04980-y>
- 410 Dimeglio, C., Herin, F., Da-Silva, I., Porcheron, M., Martin-Blondel, G., Chapuy-Regaud, S., Izopet, J.,
411 2022a. Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
412 Antibody Kinetics and Protection Duration. *Clin Infect Dis* 75, e924–e925.
413 <https://doi.org/10.1093/cid/ciab984>
- 414 Dimeglio, C., Herin, F., Martin-Blondel, G., Miedougé, M., Izopet, J., 2022b. Antibody titers and
415 protection against a SARS-CoV-2 infection. *Journal of Infection* 84, 248–288.
416 <https://doi.org/10.1016/j.jinf.2021.09.013>
- 417 Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R., Dull, P.,
418 Plotkin, S.A., 2021. Evidence for antibody as a protective correlate for COVID-19 vaccines.
419 *Vaccine* 39, 4423–4428. <https://doi.org/10.1016/j.vaccine.2021.05.063>
- 420 Eyran, T., Vaisman-Mentesh, A., Taussig, D., Dror, Y., Aizik, L., Kigel, A., Rosenstein, S., Bahar, Y.,
421 Ini, D., Tur-Kaspa, R., Kournos, T., Marcoviciu, D., Dicker, D., Wine, Y., 2022. Longitudinal
422 kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months. *PLoS Pathog*
423 18, e1010569. <https://doi.org/10.1371/journal.ppat.1010569>
- 424 Feng, S., Phillips, D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S.C.,
425 Hirsch, I., Humphries, H.E., Jepson, B., Kelly, E.J., Plested, E., Shoemaker, K., Thomas,
426 K.M., Vekemans, J., Villafana, T.L., Lambe, T., Pollard, A.J., Voysey, M., 2021. Correlates of
427 protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* 27, 2032–
428 2040. <https://doi.org/10.1038/s41591-021-01540-1>
- 429 Fenwick, C., Turelli, P., Pellaton, C., Farina, A., Campos, J., Raclot, C., Pojer, F., Cagno, V., Nusslé,
430 S.G., D'Acromont, V., Fehr, J., Puhon, M., Pantaleo, G., Trono, D., 2021. A high-throughput
431 cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-
432 19 convalescent plasma. *Sci Transl Med* 13, eabi8452.
433 <https://doi.org/10.1126/scitranslmed.abi8452>
- 434 Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., Bayer, S., Solis, M., Laugel,
435 E., Reix, N., Schneider, A., Glady, L., Panaget, B., Collongues, N., Partisani, M., Lessinger,
436 J.-M., Fontanet, A., Rey, D., Hansmann, Y., Kling-Pillitteri, L., Schwartz, O., Sèze, J.D.,
437 Meyer, N., Gonzalez, M., Schmidt-Mutter, C., Fafi-Kremer, S., 2021. Evolution of antibody
438 responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *eBioMedicine*
439 71. <https://doi.org/10.1016/j.ebiom.2021.103561>

- 440 Genecand, C., Mongin, D., Koegler, F., Lebowitz, D., Regard, S., Falcone, J.-L., Nehme, M., Brillard,
441 O., Grira, M., Joubert, D., Chopard, P., Delaporte, E., Stirnemann, J., Guessous, I., Tardin,
442 A., Courvoisier, D.S., 2021. Cohort profile: Actionable Register of Geneva Outpatients and
443 inpatients with SARS-CoV-2 (ARGOS). *BMJ Open* 11, e048946.
444 <https://doi.org/10.1136/bmjopen-2021-048946>
- 445 Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou, H.,
446 Houchens, C.R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B.C., O'Connell,
447 S., McDanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., Borate, B., van der Laan,
448 L.W.P., Hejazi, N.S., Huynh, C., Miller, J., El Sahly, H.M., Baden, L.R., Baron, M., De La
449 Cruz, L., Gay, C., Kalams, S., Kelley, C.F., Andrasik, M.P., Kublin, J.G., Corey, L., Neuzil,
450 K.M., Carpp, L.N., Pajon, R., Follmann, D., Donis, R.O., Koup, R.A., Immune Assays Team,
451 Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy
452 (COVE) Team, UNITED STATES GOVERNMENT (USG)/COVPN BIostatistics Team,
453 2022. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
454 *Science* 375, 43–50. <https://doi.org/10.1126/science.abm3425>
- 455 Goldblatt, D., Fiore-Gartland, A., Johnson, M., Hunt, A., Bengt, C., Zavadska, D., Snipe, H.D., Brown,
456 J.S., Workman, L., Zar, H.J., Montefiori, D., Shen, X., Dull, P., Plotkin, S., Siber, G.,
457 Ambrosino, D., 2022. Towards a population-based threshold of protection for COVID-19
458 vaccines. *Vaccine* 40, 306–315. <https://doi.org/10.1016/j.vaccine.2021.12.006>
- 459 Goldblatt, D., 2022. SARS-CoV-2: from herd immunity to hybrid immunity. *Nature Reviews*
460 *Immunology*, 22(6), pp.333-334.
- 461 Hertz, T., Levy, S., Ostrovsky, D., Oppenheimer, H., Zismanov, S., Kuzmina, A., Friedman, L.M.,
462 Trifkovic, S., Brice, D., Chun-Yang, L., Shemer-Avni, Y., Cohen-Lahav, M., Amichay, D.,
463 Keren-Naus, A., Voloshin, O., Weber, G., Najjar-Debbiny, R., Chazan, B., McGargill, M.A.,
464 Webby, R., Chowers, M., Novack, L., Novack, V., Taube, R., Nesher, L., Weinstein, O., 2022.
465 Correlates of protection for booster doses of the BNT162b2 vaccine.
466 <https://doi.org/10.1101/2022.07.16.22277626>
- 467 Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao, K., Kent,
468 S.J., Triccas, J.A., Davenport, M.P., 2021. Neutralizing antibody levels are highly predictive of
469 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 27, 1205–1211. <https://doi.org/10.1038/s41591-021-01377-8>
- 471 Krammer, F., 2021. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med*
472 27, 1147–1148. <https://doi.org/10.1038/s41591-021-01432-4>
- 473 L'Huillier, A.G., Meyer, B., Andrey, D.O., Arm-Vernez, I., Baggio, S., Didierlaurent, A., Eberhardt,
474 C.S., Eckerle, I., Grasset-Salomon, C., Huttner, A., Posfay-Barbe, K.M., Royo, I.S., Pralong,
475 J.A., Vuilleumier, N., Yerly, S., Siegrist, C.-A., Kaiser, L., 2021. Antibody persistence in the
476 first 6 months following SARS-CoV-2 infection among hospital workers: a prospective
477 longitudinal study. *Clinical Microbiology and Infection* 27, 784.e1-784.e8.
478 <https://doi.org/10.1016/j.cmi.2021.01.005>
- 479 Luo, Y.R., Chakraborty, I., Yun, C., Wu, A.H.B., Lynch, K.L., 2021. Kinetics of Severe Acute
480 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Avidity Maturation and
481 Association with Disease Severity. *Clin Infect Dis* 73, e3095–e3097.
482 <https://doi.org/10.1093/cid/ciaa1389>
- 483 Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M, et al. Does a
484 humoral correlate of protection exist for SARS-CoV-2? A systematic review. *PLoS One*. 2022;17:
485 e0266852.
- 486 Pelleau, S., Woudenberg, T., Rosado, J., Donnadieu, F., Garcia, L., Obadia, T., Gardais, S.,
487 Elgharbawy, Y., Velay, A., Gonzalez, M., Nizou, J.Y., Khelil, N., Zannis, K., Cockram, C.,
488 Merklings, S.H., Meola, A., Kerneis, S., Terrier, B., de Seze, J., Planas, D., Schwartz, O.,
489 Dejardin, F., Petres, S., von Platen, C., Pellerin, S.F., Arowas, L., de Facci, L.P., Duffy, D.,
490 Cheallaigh, C.N., Dunne, J., Conlon, N., Townsend, L., Duong, V., Auerswald, H., Pinaud, L.,
491 Tondeur, L., Backovic, M., Hoen, B., Fontanet, A., Mueller, I., Fafi-Kremer, S., Bruel, T., White,
492 M., 2021. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response
493 and Serological Estimation of Time Since Infection. *J Infect Dis* 224, 1489–1499.
494 <https://doi.org/10.1093/infdis/jiab375>

- 495 Peluso, M.J., Takahashi, S., Hakim, J., Kelly, J.D., Torres, L., Iyer, N.S., Turcios, K., Janson, O.,
496 Munter, S.E., Thanh, C., Donatelli, J., Nixon, C.C., Hoh, R., Tai, V., Fehrman, E.A.,
497 Hernandez, Y., Spinelli, M.A., Gandhi, M., Palafox, M.-A., Vallari, A., Rodgers, M.A., Prostko,
498 J., Hackett, J., Trinh, L., Wrin, T., Petropoulos, C.J., Chiu, C.Y., Norris, P.J., DiGermanio, C.,
499 Stone, M., Busch, M.P., Elledge, S.K., Zhou, X.X., Wells, J.A., Shu, A., Kurtz, T.W., Pak, J.E.,
500 Wu, W., Burbelo, P.D., Cohen, J.I., Rutishauser, R.L., Martin, J.N., Deeks, S.G., Henrich,
501 T.J., Rodriguez-Barrquer, I., Greenhouse, B., 2021. SARS-CoV-2 antibody magnitude and
502 detectability are driven by disease severity, timing, and assay. *Sci Adv* 7, eabh3409.
503 <https://doi.org/10.1126/sciadv.abh3409>
- 504 Perez-Saez, J., Zaballa, M.-E., Yerly, S., Andrey, D.O., Meyer, B., Eckerle, I., Balavoine, J.-F.,
505 Chappuis, F., Pittet, D., Trono, D., Kherad, O., Vuilleumier, N., Kaiser, L., Guessous, I.,
506 Stringhini, S., Azman, A.S., 2021. Persistence of anti-SARS-CoV-2 antibodies: immunoassay
507 heterogeneity and implications for serosurveillance. *Clinical Microbiology and Infection*.
508 <https://doi.org/10.1016/j.cmi.2021.06.040>
- 509 Springer, D.N., Perkmann, T., Jani, C.M., Mucher, P., Prüger, K., Marculescu, R., Reuberger, E.,
510 Camp, J.V., Graninger, M., Borsodi, C., Deutsch, J., Lammel, O., Aberle, S.W., Puchhammer-
511 Stöckl, E., Haslacher, H., Hörtl, E., Aberle, J.H., Stiasny, K., Weseslindtner, L., 2022.
512 Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection
513 with the SARS-CoV-2 Omicron Variant. *Microbiology Spectrum* 10, e02129-22. <https://doi.org/10.1128/spectrum.02129-22>
- 515 Stringhini, S., Wisniak, A., Piumatti, G., Azman, A.S., Lauer, S.A., Baysson, H., De Ridder, D.,
516 Petrovic, D., Schrempft, S., Marcus, K., Yerly, S., Arm Vernez, I., Keiser, O., Hurst, S.,
517 Posfay-Barbe, K.M., Trono, D., Pittet, D., Gétaz, L., Chappuis, F., Eckerle, I., Vuilleumier, N.,
518 Meyer, B., Flahault, A., Kaiser, L., Guessous, I., 2020. Seroprevalence of anti-SARS-CoV-2
519 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *Lancet*
520 396, 313–319. [https://doi.org/10.1016/S0140-6736\(20\)31304-0](https://doi.org/10.1016/S0140-6736(20)31304-0)
- 521 Stringhini, S., Zaballa, M.-E., Perez-Saez, J., Pullen, N., de Mestral, C., Picazio, A., Pennacchio, F.,
522 Wisniak, A., Richard, A., Baysson, H., others, 2021a. Seroprevalence of anti-SARS-CoV-2
523 antibodies after the second pandemic peak. *The Lancet. Infectious Diseases* 21, 600–601.
- 524 Stringhini, S., Zaballa, M.-E., Pullen, N., de Mestral, C., Perez-Saez, J., Dumont, R., Picazio, A.,
525 Pennacchio, F., Dibner, Y., Yerly, S., Baysson, H., Vuilleumier, N., Balavoine, J.-F.,
526 Bachmann, D., Trono, D., Pittet, D., Chappuis, F., Kherad, O., Kaiser, L., Azman, A.S.,
527 Guessous, I., 2021b. Large variation in anti-SARS-CoV-2 antibody prevalence among
528 essential workers in Geneva, Switzerland. *Nat Commun* 12, 3455.
529 <https://doi.org/10.1038/s41467-021-23796-4>
- 530 Tan, C.-W., Lim, B.-L., Young, B.E., Yeoh, A.Y.-Y., Yung, C.-F., Yap, W.-C., Althaus, T., Chia, W.-N.,
531 Zhu, F., Lye, D.C., Wang, L.-F., 2022. Comparative neutralisation profile of SARS-CoV-2
532 omicron subvariants BA.2.75 and BA.5. *The Lancet Microbe* 0. [https://doi.org/10.1016/S2666-5247\(22\)00220-8](https://doi.org/10.1016/S2666-5247(22)00220-8)
- 534 Theel, E.S., Slev, P., Wheeler, S., Couturier, M.R., Wong, S.J., Kadkhoda, K., 2020. The Role of
535 Antibody Testing for SARS-CoV-2: Is There One? *J Clin Microbiol* 58, e00797-20.
536 <https://doi.org/10.1128/JCM.00797-20>
- 537 Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell,
538 H., Schlotz, M., Ercanoglu, M.S., Stumpf, R., Mayer, P., Zehner, M., Heger, E., Johannis, W.,
539 Horn, C., Suárez, I., Jung, N., Salomon, S., Eberhardt, K.A., Gathof, B., Fätkenheuer, G.,
540 Pfeifer, N., Eggeling, R., Augustin, M., Lehmann, C., Klein, F., 2021. Kinetics and correlates
541 of the neutralizing antibody response to SARS-CoV-2 infection in humans. *Cell Host Microbe*
542 29, 917-929.e4. <https://doi.org/10.1016/j.chom.2021.04.015>
- 543 Wal, W.M. van der, Geskus, R.B., 2011. ipw: An R Package for Inverse Probability Weighting. *Journal*
544 *of Statistical Software* 43, 1–23. <https://doi.org/10.18637/jss.v043.i13>
- 545 Wei, J., Stoesser, N., Matthews, P.C., Ayoubkhani, D., Studley, R., Bell, I., Bell, J.I., Newton, J.N.,
546 Farrar, J., Diamond, I., Rourke, E., Howarth, A., Marsden, B.D., Hoosdally, S., Jones, E.Y.,
547 Stuart, D.I., Crook, D.W., Peto, T.E.A., Pouwels, K.B., Eyre, D.W., Walker, A.S., COVID-19
548 Infection Survey team, 2021. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults
549 from the general population of the United Kingdom. *Nat Microbiol* 6, 1140–1149.
550 <https://doi.org/10.1038/s41564-021-00947-3>

- 551 Zaballa, M.-E., Perez-Saez, J., Mestral, C. de, Pullen, N., Lamour, J., Turelli, P., Raclot, C., Baysson,
552 H., Pennacchio, F., Villers, J., Duc, J., Richard, V., Dumont, R., Semaani, C., Loizeau, A.J.,
553 Graindorge, C., Lorthe, E., Balavoine, J.-F., Pittet, D., Schibler, M., Vuilleumier, N., Chappuis,
554 F., Kherad, O., Azman, A.S., Posfay-Barbe, K.M., Kaiser, L., Trono, D., Stringhini, S.,
555 Guessous, I., Group, the S.-C. study, 2022. Seroprevalence of anti-SARS-CoV-2 antibodies
556 and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva,
557 Switzerland. <https://doi.org/10.1101/2022.07.27.22278126>
- 558 Zar, H.J., MacGinty, R., Workman, L., Botha, M., Johnson, M., Hunt, A., Burd, T., Nicol, M.P.,
559 Flasche, S., Quilty, B.J., Goldblatt, D., 2022. Natural and hybrid immunity following four
560 COVID-19 waves: A prospective cohort study of mothers in South Africa. *eClinicalMedicine*
561 53, 101655. <https://doi.org/10.1016/j.eclinm.2022.101655>
- 562